Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

RGNX vs XNCR: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

XNCR Wins Head-to-Head Institutional Verdict (4–2 across 6 Pillars · 8–2 Matrix Metrics)

XNCR Overall Winner 6-Pillar Tally: RGNX 2 – 4 XNCR Matrix Metrics: RGNX 2 – 8 XNCR

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas XNCR carries 29.6/100 (SELL) at $35.62 (68.0x Forward P/E, -72.7% operating margin).

  • Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -120.4% operating margin) and revenue trajectory (+454.9% vs. -69.2% YoY).
  • Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About RGNX vs XNCR
RGNX NASDAQ
REGENXBIO Inc.
Biological Products, (No Disgnostic Substances)
$7.47
-2.23% 1D
Market Cap $500.9M
TTM Revenue $154M
Forward P/E N/M
Beta / 30D Vol 1.81β · 76% Vol
Unified Composite Score
45.3 / 100 HOLD
Tech 36.0 Fund 44.0 Flow 69.0 Mom 50.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -12.2%) with fading momentum, RSI 48
RSI-14: 48.3 · SMA20: $7.42 · SMA50: $7.63
XNCR NASDAQ Head-to-Head Winner
Xencor, Inc.
Pharmaceutical Preparations
$35.62
-3.98% 1D
Market Cap $2.9B
TTM Revenue $200M
Forward P/E 68.0x
Beta / 30D Vol 1.19β · 86% Vol
Unified Composite Score
29.6 / 100 SELL
Tech 50.0 Fund 32.0 Flow 66.0 Mom 40.0
Weinstein Technical Phase Markup · Hold / add on dips
Price above SMA50, rising 50-day trend (9.7% over 20 days), RSI 62
RSI-14: 62.5 · SMA20: $32.16 · SMA50: $27.52

6-Pillar Scorecard Institutional Category Breakdown (RGNX 2 – 4 XNCR)

Columns: Metric · RGNX · XNCR
1. Valuation Multiples XNCR
Forward P/E N/M 68.0x
Trailing P/E N/M 68.0x
PEG Ratio 0.26x N/M
EV / Revenue 3.1x 14.8x
2. Growth & Scale XNCR
Revenue Growth (YoY) -69.2% +454.9%
Earnings Growth (YoY) +0.0% +0.0%
TTM Revenue (USD) $154M $200M
Market Cap $500.9M $2.9B
3. Profitability & Quality XNCR
Gross Margin -64.5% -42.5%
Operating Margin -120.4% -72.7%
Net Profit Margin -113.9% -58.8%
Return on Equity (ROE) -113.2% -19.9%
4. Balance Sheet & Cash Flow RGNX
Cash Generation (TTM) -$155M -$176M
Cash Flow Margin -100.6% -88.0%
Net Cash / Leverage $29M Net Cash $101M Net Debt (0.29x D/E)
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning XNCR
Options Structure Phase BREAKDOWN BREAKOUT
Current IV / %ile 349.6% (52nd %ile) 79.0% (10th %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase ACCUMULATION · Distribution ACCUMULATION · Markup
6. R&D & Supply-Chain Moat RGNX
OpEx & R&D Intensity 55.9% of Rev ($86M) 30.2% of Rev ($61M)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Cyclical / Execution-Driven Positioning Cyclical / Execution-Driven Positioning
Supply-Chain Role Biotechnology Operator Biotechnology Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: RGNX (2) vs XNCR (8)
Institutional Metric RGNX XNCR Criterion Row Edge
Market Capitalization
Scale
$500.9M $2.9B Larger Scale XNCR
Trailing P/E Ratio
Valuation
N/M 68.0x Lower Multiple XNCR
Forward P/E Ratio
Valuation
N/M 68.0x Lower Multiple XNCR
Revenue Growth (YoY)
Growth
-69.2% +454.9% Higher Growth XNCR
Operating Margin (TTM)
Profitability
-120.4% -72.7% Higher Margin XNCR
Net Profit Margin
Profitability
-113.9% -58.8% Higher Margin XNCR
Return on Equity (ROE)
Capital Efficiency
-113.2% -19.9% Higher ROE XNCR
52-Week Range Position
Momentum
19% ($5–$16) 84% ($10–$41) Stronger Trend XNCR
Beta / 30D Volatility
Risk Regime
1.81β · 76% Vol 1.19β · 86% Vol Lower Realized Risk RGNX
Unified Institutional Score
Composite Signal
45.3 / 100 (HOLD) 29.6 / 100 (SELL) Higher Composite RGNX
Trailing 12M Revenue (USD)
Operating Scale
$154M $200M FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
-64.5% -42.5% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
0.26x PEG · 3.1x EV/Rev N/M PEG · 14.8x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
-$155M ($29M Net Cash) -$176M ($101M Net Debt (0.29x D/E)) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon XNCR +47.99 pp
RGNX: +7.87% · XNCR: +55.86%
3M Horizon XNCR +72.68 pp
RGNX: -32.52% · XNCR: +40.16%
6M Horizon XNCR +189.81 pp
RGNX: +32.21% · XNCR: +222.02%
1Y Horizon XNCR +190.39 pp
RGNX: -35.82% · XNCR: +154.57%

Financial Trajectory Multi-Year Annual Revenue & Operating Margin Trajectory (USD)

Split-Invariant USD Revenue & Operating Margin (%)
Period RGNX Revenue XNCR Revenue RGNX Op. Margin XNCR Op. Margin Margin Leader
FY2018 $220M $40M 40.3% -195.5% RGNX
FY2019 $40M $160M -422.9% 8.8% XNCR
FY2020 $150M $120M -77.1% -62.6% XNCR
FY2021 $470M $280M 34.0% 15.9% RGNX
FY2022 $110M $160M -233.2% -50.1% XNCR
FY2023 $90M $170M -297.1% -75.8% XNCR
FY2024 $80M $110M -280.0% -161.5% XNCR
FY2025 $170M $130M -94.6% -141.4% RGNX

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
RGNX BREAKDOWN
91d in phase · OBV ACCUMULATION
Current IV 349.6%
IV Percentile 52nd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BULLISH
OBV Flow ACCUMULATION
Exact RGNX Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
XNCR BREAKOUT
58d in phase · OBV ACCUMULATION
Current IV 79.0%
IV Percentile 10th %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal BEARISH
OBV Flow ACCUMULATION
Exact XNCR Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
RGNX Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $500.9M market capitalization and -120.4% operating margin.
OpEx & R&D Reinvestment 55.9% of Rev ($86M)
90D Engineering Disclosures 0 Published
XNCR Moat Profile Cyclical / Execution-Driven Positioning
Biotechnology Operator
Competes within the Biotechnology value chain with $2.9B market capitalization and -72.7% operating margin.
OpEx & R&D Reinvestment 30.2% of Rev ($61M)
90D Engineering Disclosures 0 Published

Investor FAQ RGNX vs XNCR Key Questions & Quantitative Answers

As of Nov 16, 2026, Xencor, Inc. (XNCR) is the stronger overall head-to-head candidate over REGENXBIO Inc. (RGNX) in the Tradestie Institutional Equity Comparison Engine, winning 8–2 core matrix metrics and 4–2 across our 6-pillar institutional scorecard (led by Valuation Multiples, Growth & Scale, Profitability & Quality). RGNX carries a Unified Composite Score of 45.3/100 (HOLD) at $7.47 (N/M Forward P/E, -120.4% operating margin), whereas XNCR carries 29.6/100 (SELL) at $35.62 (68.0x Forward P/E, -72.7% operating margin). Composite vs. Pillar Nuance: While RGNX currently prints a higher short-term Unified Composite Score (45.3/100 HOLD vs. XNCR 29.6/100 SELL), XNCR captures the overall institutional head-to-head verdict (8–2 matrix metrics and 4–2 across the 6 pillars) due to superior fundamental profitability (-72.7% vs. -120.4% operating margin) and revenue trajectory (+454.9% vs. -69.2% YoY). Technical & Structure Timing Caution: RGNX is currently in a Weinstein Distribution regime near a flattening 50-day moving average and Breakdown options structure phase (RSI 48.3); meanwhile XNCR trades in a Markup technical trend (BREAKOUT options phase, RSI 62.5). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

XNCR leads the Growth & Scale pillar: RGNX posts -69.2% YoY revenue growth and +0.0% YoY earnings growth on $154M TTM revenue (-64.5% gross margin, -120.4% operating margin), compared with XNCR at +454.9% YoY revenue growth and +0.0% YoY earnings growth on $200M TTM revenue (-42.5% gross margin, -72.7% operating margin). Across the 8-period historical trajectory (FY2018 to FY2025), RGNX cumulative revenue shifted -22.7% while XNCR shifted +225.0%. In operating R&D and SG&A reinvestment, RGNX deploys 55.9% of Rev ($86M) (0 90-day corporate R&D disclosures) versus 30.2% of Rev ($61M) (0 disclosures) for XNCR.

XNCR screens cheaper on headline valuation multiples. RGNX trades at N/M Forward P/E, N/M Trailing P/E, 0.26x PEG, and 3.1x EV/Revenue (-100.6% FCF margin), whereas XNCR trades at 68.0x Forward P/E, 68.0x Trailing P/E, N/M PEG, and 14.8x EV/Revenue (-88.0% FCF margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against RGNX (-113.2% ROE) versus XNCR (-19.9% ROE) capital efficiency.

In options market volatility and institutional positioning, RGNX carries 349.6% implied volatility (52nd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKDOWN options structure phase (1.81β · 76% Vol realized risk). By comparison, XNCR carries 79.0% implied volatility (10th %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, ACCUMULATION on-balance volume, and sits in a BREAKOUT options structure phase (1.19β · 86% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.